Is Kailera Therapeutics a Buy After Its Sizzling IPO?

In the biotech sector, private companies are moving from the sidelines into the spotlight through initial public offerings (IPOs). One of the most recent is Kailera Therapeutics (NASDAQ: KLRA), a potential competitor to Eli Lilly and Novo Nordisk in the obesity treatment market with its weight-loss drug candidates.The company priced its initial public offering (IPO) at $16 per share, opening to the public on April 17 at $26 per share. The stock price has recently cooled, but with its promising drug pipeline, investors are wondering whether this is an opening for buying shares for the long term.Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool